We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to... FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc. Show more
HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on...
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on...
HOUSTON, June 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on...
HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.1667 | 3.32734530938 | 5.01 | 5.49 | 4.42 | 190926 | 4.86295893 | CS |
| 4 | -1.5233 | -22.7358208955 | 6.7 | 7.04 | 3.9 | 445039 | 4.88507645 | CS |
| 12 | -5.4733 | -51.3924882629 | 10.65 | 13.59 | 3.9 | 254658 | 7.06458264 | CS |
| 26 | -24.8233 | -82.7443333333 | 30 | 55 | 3.9 | 177472 | 8.62377385 | CS |
| 52 | -24.8233 | -82.7443333333 | 30 | 55 | 3.9 | 177472 | 8.62377385 | CS |
| 156 | -24.8233 | -82.7443333333 | 30 | 55 | 3.9 | 177472 | 8.62377385 | CS |
| 260 | -24.8233 | -82.7443333333 | 30 | 55 | 3.9 | 177472 | 8.62377385 | CS |
Invest-in-America
1 month ago
tw0122
1 month ago
enthalpy
5 months ago
Monksdream
5 months ago
Invest-in-America
5 months ago
GhosTraderX
5 months ago
TheFinalCD
5 months ago
Monksdream
5 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
